The present disclosure pertains compositions comprising anti-VEGF proteins and methods for producing such compositions.

A novel luciferase with a small molecular weight is provided. A polypeptide with luciferase activity comprising an amino acid sequence (A) or (B) is provided:

(A) an amino acid sequence as set forth in SEQ ID NO: 1 with deletion of amino acid residues at positions 1 to 69 and 204 to 221; or

(B) an amino acid sequence as set forth in SEQ ID NO: 1 with deletion of amino acid residues at positions 1 to 69 and deletion or substitution of at least one of amino acid residues 146 to 156.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using anion exchange chromatography to produce aflibercept with a specific glycosylation profile. In particular, these methods produce aflibercept with a glycosylation profile with specific ranges of % total fucosylated glycans, total sialylated glycans, mannose-5, and galactosylated glycans.

The present disclosure pertains to methods for preparing a prefilled syringe and methods for preparing an auto injector prefilled syringe comprising aflibercept and methods for producing such aflibercept in chemically defined media.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.